Cryogenic Solutions Inc. (CYGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: celeryroot.com who wrote (3207)	8/19/1998 3:19:00 PM
From: Graham Marshman	Read Replies (2) of 4028

An IND is submitted when a company wishes to move from preclinical stage into FDA controlled clinical trials. Good reference on general process is here: barrlabs.com Well CYGS right now could be said to be in between stages. If pre-clinical testing has proven the effectiveness of their basic product, then it can be held to have finished. It may be continuing however on either different or extension projects, for instance expanding the cell types supported. Since they have not announced either issuance of an IND or any FDA program, they are not in clinical trial status. Re time and cost, we can only hope that some of the recent FDA reform measures continue to reduce both. It's also difficult to say what would happen to existing clinical trials that an antisense molecule owner may be involved in if they decided to use the CYGS delivery vector. Graham

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next